Literature DB >> 25456937

Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?

Laura Y Wang1, Iain J Nixon1, Frank L Palmer1, Dorothy Thomas1, R Michael Tuttle2, Ashok R Shaha1, Snehal G Patel1, Jatin P Shah1, Ian Ganly3.   

Abstract

INTRODUCTION: The current American Joint Committee on Cancer TNM classification for differentiated thyroid cancer (DTC) separates T1 status into T1a and T1b based on a 1-cm cutoff for maximal tumor dimension. In 2009, the American Thyroid Association recommended total thyroidectomy for tumors >1 cm in contrast to the possibility of lobectomy for tumors ≤ 1 cm. Our aim was to investigate the prognostic significance of a 1-cm tumor cutoff.
METHODS: From an institutional database of 3,664 patients with DTC, 1,522 patients with T1 tumors without neck disease or distant metastases were identified. Patient, tumor, and treatment characteristics were compared. Disease-specific survival (DSS) and recurrence-free survival (RFS) outcomes were analyzed.
RESULTS: Total thyroidectomy rates were similar between patients with T1a and T1b tumors (P = .307). With a median follow-up of 46 months (range, 1-320), there were no disease-specific deaths in the T1a or T1b groups. In total, 18 patients (1.2%) experienced a recurrence. Five-year RFS was comparable for patients with T1a and T1b tumors (98.6 vs 98.6%; P = .224).
CONCLUSION: T1a and T1b tumors have similar prognosis both in terms of DSS and RFS. It seems that a distinction between tumors of <1 and >1 cm is of no prognostic benefit.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25456937     DOI: 10.1016/j.surg.2014.08.037

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Does the T1 subdivision correlate with the risk of recurrence of papillary thyroid cancer?

Authors:  Nathalie Chereau; Christophe Trésallet; Severine Noullet; Gaelle Godiris-Petit; Frédérique Tissier; Laurence Leenhardt; Fabrice Menegaux
Journal:  Langenbecks Arch Surg       Date:  2016-03-08       Impact factor: 3.445

Review 2.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

3.  T1a Versus T1b Differentiated Thyroid Cancers: Do We Need to Make the Distinction?

Authors:  Kevin L Anderson; Linda M Youngwirth; Randall P Scheri; Michael T Stang; Sanziana A Roman; Julie A Sosa
Journal:  Thyroid       Date:  2016-07-06       Impact factor: 6.568

4.  The Prognostic Values of Preoperative Tumor Volume and Tumor Diameter in T1N0 Papillary Thyroid Cancer.

Authors:  Seung Taek Lim; Ye Won Jeon; Young Jin Suh
Journal:  Cancer Res Treat       Date:  2016-12-13       Impact factor: 4.679

5.  Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis.

Authors:  Chunping Liu; Shuntao Wang; Wen Zeng; Yawen Guo; Zeming Liu; Tao Huang
Journal:  Sci Rep       Date:  2017-05-12       Impact factor: 4.379

6.  Treatment strategies and predicting lymph node metastasis in elderly patients with papillary thyroid microcarcinoma.

Authors:  Wenhan Li; Yao Tang; Jianhui Li; Wei Han; Danfang Wang; Yongheng Wang
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 7.  Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now.

Authors:  Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

8.  Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma.

Authors:  Sandeep Kumar Parvathareddy; Abdul K Siraj; Zeeshan Qadri; Saeeda O Ahmed; Felisa DeVera; Saif Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya
Journal:  Endocr Connect       Date:  2022-02-16       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.